泰林生物(300813.SZ)業績快報:2019年度淨利潤降24.07%至3661萬元
格隆匯2月28日丨泰林生物(300813.SZ)披露2019年度業績快報,公司2019年度實現營業收入1.83億元,較上年同期增長14.81%;利潤總額4077.54萬元,同比下降24.07%;歸屬於上市公司股東的淨利潤3661.00萬元,同比下降24.07%;基本每股收益0.94元。
公司的收入比去年同期有所增長,但利潤總額和歸屬於上市公司股東的淨利潤較去年同期有所下降主要原因是:公司各項業務穩健開展,銷售收入持續增長,但國家重大專項研發投入加大及新的生產基地投入使用等因素也導致營運成本和費用增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.